Kazia KZIA 深 滬
已收盤 01-09 16:00:00 美东时间
6.82
+0.040
+0.59%
華盛通- 最 高7.08
- 今 開6.78
- 成交量 24.05万股
- 最 低 6.53
- 昨 收 6.78
- 總市值 1104.02万
- 52周最高 17.40
- 市盈率 靜 --
- 換手率 14.86%
- 52周最低 2.90
- 委 比 37.30%
- 總股本 161.88万
- 歷史最高 744.50
- 量 比 0.73
- 振 幅 8.11%
- 歷史最低 3.005
- 每 手 1
- 風險率 2.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多How $594B in Precision Tech is Cracking the Metastatic Cancer Code
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is surging toward $594.3 billion by 2...
01-07 23:32
Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?
Kazia Therapeutics Ltd's (NYSE:KZIA) short interest as a percent of float has f...
2025-12-27 01:00
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" o...
2025-12-22 21:00
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Kazia Therapeutics Says First Patient From TNBC Trial Demonstrated 76% Tumor Volume Shrinkage With Corresponding Reductions In CTC And Clusters
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clustersReinvigoration of immune system + turning cold tumors hotPreliminary
2025-12-10 21:07
What's Going On With Cancer Firm Kazia Therapeutics
Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical development and extend cash runway.
2025-12-03 01:21
Kazia Therapeutics Announces ~$50M PIPE, Selling Ordinary Shares And Pre-Funded Warrants At A Price Equivalent To $5.00 Per ADS, Each ADS Representing 500 Ordinary Shares, With Expected Net Proceeds Of ~$46.5M
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited
2025-12-02 22:06
Market-Moving News for November 19th
LOW: 6% | Lowe's shares are trading higher despite mixed Q3 financial results. The company raised FY25 sales guidance. PLUG: -22% | Plug Power shares are trading lower after the company announced a $375
2025-11-19 20:21
What Sparked Kazia Therapeutics' Over 51% After-Hours Surge?
Kazia Therapeutics jumped 51.74% in after-hours trading Tuesday after reporting a rare immune-complete response in a patient.
2025-11-19 16:52
Kazia Therapeutics shares are trading higher after the company reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol combining paxalisib with pembrolizumab and chemotherapy.
Kazia Therapeutics shares are trading higher after the company reported an init...
2025-11-19 05:19
